Enhanced Epitopic Diversity for Your Most Challenging Targets
The limitation of most in vivo discovery platforms is the diversity of the host animal's immune response. The DiversimAb™ mouse platform is designed to deliver maximum antibody diversity. Our proprietary mice can generate rare murine antibodies against epitopes and proteins with high homology to mouse orthologs. By combining Twist’s industry-leading hybridoma and deep B cell screening platforms with DiversimAb, targeting even the most challenging targets is possible.
Our platform is commonly used for generating various types of antibodies
It also produces antibodies targeting cell surface receptors, anti-mouse surrogate antibodies, and essential anti-idiotype reagents.
Therapeutic and reagent antibodies
Antibodies with customized cross-reactivity
Highly specific antibodies
Potent antibodies
Comparing Antibody Titers from DiversimAb™ and Balb/c Mice
We’ve analyzed antibody responses for DiversimAb mice, DiversimAb mice pre-immunization, and Balb/c mice across antigen homologies of 75%, 87%, 96%, and 100%. At each level of homology, the cohort of DiversimAb mice (green) had the most potent antibody response, followed by the Balb/c mice (purple) with a moderate response and the pre-immune DiversimAb group (gold) with minimal response. Across all dilutions, from 1:300 to 1:72900, DiversimAb mice consistently demonstrate a superior antibody response, even when immunizing with an antigen of 100% homology.
Enhanced Epitopic Diversity for Your Most Challenging Targets
The limitation of most in vivo discovery platforms is the diversity of the host animal's immune response. The DiversimAb™ mouse platform is designed to deliver maximum antibody diversity. Our proprietary mice can generate rare murine antibodies against epitopes and proteins with high homology to mouse orthologs. By combining Twist’s industry-leading hybridoma and deep B cell screening platforms with DiversimAb, targeting even the most challenging targets is possible.
Our platform is commonly used for generating various types of antibodies
It also produces antibodies targeting cell surface receptors, anti-mouse surrogate antibodies, and essential anti-idiotype reagents.
Therapeutic and reagent antibodies
Antibodies with customized cross-reactivity
Highly specific antibodies
Potent antibodies
Comparing Antibody Titers from DiversimAb™ and Balb/c Mice
We’ve analyzed antibody responses for DiversimAb mice, DiversimAb mice pre-immunization, and Balb/c mice across antigen homologies of 75%, 87%, 96%, and 100%. At each level of homology, the cohort of DiversimAb mice (green) had the most potent antibody response, followed by the Balb/c mice (purple) with a moderate response and the pre-immune DiversimAb group (gold) with minimal response. Across all dilutions, from 1:300 to 1:72900, DiversimAb mice consistently demonstrate a superior antibody response, even when immunizing with an antigen of 100% homology.
A Different Discovery Experience with DiversimAb™
通过用于抗体工程和优化的全面工具和服务，探索更多。我们的 TAO 平台提供抗体工程师的科学专业知识和创新技术，以加速您的生物发现和开发。
增强的抗体多样性
DiversimAb™ mice provide an advantage in nearly any custom antibody discovery application due to the increased epitopic diversity of the mAbs generated. As a benefit of enhanced antibody diversities, the DiversimAb™ platform readily enables the discovery of species' cross-reactive antibodies, including human, cyno, and mouse cross-reactive antibodies.
Difficult, High-Homology Epitope Targeting
Our auto-immune, hyperimmune model enables the delivery of antibodies against difficult targets, including cell surface receptors and epitopes that do not elicit a robust immune response in natural mice. We've delivered antibodies against 100% Mus musculus proteins using DiversimAb™ mice.
Purpose-Built and Rapid Immunization Strategies for Tough Targets
Twist uses proprietary, customizable immunization protocols optimized for DiversimAb™ for multipass membrane proteins including GPCRs, ion channels, high-homology targets, and poor immunogens. These rapid immunization strategies can elicit robust immune responses in weeks rather than months, delivering leads without sacrificing affinity or quality.
Royalty-Free Use
Twist offers royalty-free, flexible business models, including fee-for-service and partnership structures, to access our DiversimAb™ platform for your most challenging targets and high-profile programs.
A Different Discovery Experience with DiversimAb™
通过用于抗体工程和优化的全面工具和服务，探索更多。我们的 TAO 平台提供抗体工程师的科学专业知识和创新技术，以加速您的生物发现和开发。
增强的抗体多样性
DiversimAb™ mice provide an advantage in nearly any custom antibody discovery application due to the increased epitopic diversity of the mAbs generated. As a benefit of enhanced antibody diversities, the DiversimAb™ platform readily enables the discovery of species' cross-reactive antibodies, including human, cyno, and mouse cross-reactive antibodies.
Difficult, High-Homology Epitope Targeting
Our auto-immune, hyperimmune model enables the delivery of antibodies against difficult targets, including cell surface receptors and epitopes that do not elicit a robust immune response in natural mice. We've delivered antibodies against 100% Mus musculus proteins using DiversimAb™ mice.
Purpose-Built and Rapid Immunization Strategies for Tough Targets
Twist uses proprietary, customizable immunization protocols optimized for DiversimAb™ for multipass membrane proteins including GPCRs, ion channels, high-homology targets, and poor immunogens. These rapid immunization strategies can elicit robust immune responses in weeks rather than months, delivering leads without sacrificing affinity or quality.
Royalty-Free Use
Twist offers royalty-free, flexible business models, including fee-for-service and partnership structures, to access our DiversimAb™ platform for your most challenging targets and high-profile programs.
技术资源
技术资源
联系我们
我们的抗体专家随时待命，并希望听到更多关于您的发现需求的信息。欢迎挑战性目标！
